Novocure Stock Earnings Reports

NovoCure reported a strong start to 2026 with double-digit year-over-year growth in active patients and net revenue. The quarter was highlighted by FDA approval and initial U.S. commercial launch of Optune Pax for locally advanced pancreatic cancer, with early commercial metrics showing 868 certified HCPs, 169 prescriptions, 90 patient starts and 83 patients on therapy by quarter end; the company also secured a major payer coverage policy (Elevance Health). PANOVA-4 (metastatic pancreatic cancer) met its primary endpoint, supporting feasibility of TTFields in metastatic disease, and preclinical data suggest potential synergy between TTFields and KRAS inhibitors. Optune Gio (GBM) remains the core business with 9% global active patient growth, and the TRIDENT Phase III readout (on TTFields with radiation) is expected in Q2. Optune Lua began national reimbursement and commercial treatment in Japan. NovoCure raised full-year revenue guidance to $690M–$710M (5%–8% growth) and updated adjusted EBITDA guidance to negative $15M to breakeven, reflecting strong execution and Pax launch expenses. Gross margin improved to 78% in Q1; R&D and S&M costs rose on trials and launches; GAAP net loss widened due to a one-time $43M share-based compensation charge tied to Pax approval. Cash and investments were $432M at quarter end. Management reiterated focus on expanding adoption across indications, capturing value from new launches, progressing clinical catalysts, and moving toward profitability.